Page 164 - CW E-Magazine (10-9-2024)

News from Abroad

EVENT HIGHLIGHTS
CPHI Korea 2024 concludes in Seoul

Leading Korean pharmaceutical indus- decade ago, the biologics supply chain has bitors such as the National Institute of Bio-
try trade event, CPHI Korea, concluded in grown massively here and we now expect logical Resources, Honam National Institute
Seoul with participation of over 9,000 visi- this to continue alongside an international of Biological Resources, and the National
tors from around 70 countries. The event solid dose and, significantly, nutraceutical, Institute of Ecology. The Korea Biomedicine
was co-located with HI Korea and PMEC. health and wellness industry.” Industry Association co-organised the bio-
The event’s 10th edition featured over 370 zone of the event to support the country’s
exhibitors with health ingredients, nutra- Adding to the international participa- rapidly growing biopharmaceutical sector.
ceuticals and biopharma driving growth. tion, the event featured prominent Chinese CPHI Korea also featured more than 50
organisations, including the China Chamber dedicated sessions from, among others, the
Ms. Jenny Leung, Brand Manager at of Commerce for Import & Export of Medi- Korean ministry of SMEs, the Korea Drug
CPHI Korea, commented, “The event’s cines & Health Products (CCCMHPIE) Research Association and an international
a real melting pot of ideas, supply side and the China Council for the Promotion of update from the USP (US Pharmacopoeia)
technology innovators and major pharma International Trade (CCPIT). Korean local on the ‘Importance of global quality standard
players. Since CPHI Korea first opened a institutes also participated, with notable exhi- for dietary supplements’.
Rokote Labs ropes in 3PBiovian for intranasal

COVID-19 vaccine development

Finland-based vaccine development ted 3PBiovian as their CDMO partner for causing COVID-19. Such mucosal immunity
company, Rokote Laboratories, has inked GMP manufacturing of adenovirus type 5 could potentially prevent both infection and
a deal with Contract Development and (Ad5) vector-based candidate expressing transmission. The agreement covers GMP
Manufacturing Organisation (CDMO), a modified spike protein of severe acute manufacturing of the Ad5 vector for phase
3PBioVian, to produce the drug sub- respiratory coronavirus 2 (SARS-CoV-2). I clinical studies using 3Pbiovian’s standard
stance and product for its intranasal process at facilities located in Turku,
COVID-19 vaccine, ‘FINCoVac 2.1’, The ‘FINCoVac 2.1’ vaccine aims to Finland. Due to Rokote Laboratories’ urgent
ahead of phase I trials. elicit a strong mucosal immune response in needs, the programme advanced to a GMP
the nasopharyngeal cells, which serve as the batch exceptionally fast, leveraging 3PBio-
Rokote Laboratories said it has selec- primary entry point for the SARS-CoV-2 vian’s adenovirus-based process experience.

DIVESTMENT
PPG to sell silicas products business to Poland’s

Qemetica

PPG, the US-based paints, coat- and supplies precipitated silica products in Barberton, Ohio and Monroeville,
ings, and speciality materials maker, to major companies around the world Pennsylvania, respectively. The silicas
has agreed to sell its silicas business for as performance-enhancing additives. In products business is led by about 400
approximately $310-mn in pre-tax pro- 2023, the business represented between employees.
ceeds to Qemetica S.A., a Poland-based, 1-2% of PPG’s total net sales.
privately held manufacturer of soda ash, PPG’s Chairman and CEO, Mr. Tim
silicates and other speciality chemicals. The transaction includes PPG’s Knavish, said, “This transaction will
Earlier this year, PPG had announced it precipitated silicas manufacturing faci- allow us to further focus our resources on
is evaluating strategic alternatives for the lities in Lake Charles, Louisiana, and our technology-differentiated coatings
business. Delfzijl, The Netherlands. In addition, and speciality products businesses to
Qemetica will lease silicas manufactur- accelerate our organic growth and drive
PPG’s silicas business manufactures ing and R&D operations at PPG sites increased shareholder value creation.”

164 Chemical Weekly September 10, 2024

Contents Index to Advertisers Index to Products Advertised